Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

The German pharmaceutical-and-agricultural group said the acquisition would complement its drug pipeline and leverage its ophthalmology footprint.

Recent Posts

editors picks

Top Reviews